Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
REGENXBIO Inc. (RGNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights • Continued progress on ‘5x’25’ strategy to advance five AAV Therapeutics from REGENXBIO’s internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 • ABBV-RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie • Interim results from Phase II AAVIATE® and ALTITUDE® trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation • Additional interim efficacy data from the Phase II AAVIATE and ALTITUDE trials expected at upcoming medical conferences in second half 2023 and first half 2024 • Interim data f..."
06/05/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/10/2023 SC 13G/A VANGUARD GROUP INC reports a 10% stake in REGENXBIO Inc.
05/03/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/06/2023 ARS Form ARS - Annual Report to Security Holders:
04/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights - Continued progress on ‘5x’25’ strategy to advance five AAV Therapeutics from REGENXBIO’s internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 - RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie o Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials using subretinal delivery, expected to support BLA filing in 2024 o Recently announced interim data from the Phase II pharmacodynamic study supports use of NAVXpress™ platform process in future commercialization plans o Recently announced cohort expansions in AAVIATE® and ALTITUDE® suprachoroidal clinical tr..."
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9.9% stake in REGENXBIO Inc.
02/03/2023 SC 13G/A STATE STREET CORP reports a 6.3% stake in AMENDED FILING REGENXBIO INC
01/27/2023 SC 13G/A JPMORGAN CHASE & CO reports a 8.7% stake in REGENXBIO Inc.
01/23/2023 SC 13G/A BlackRock Inc. reports a 15.4% stake in REGENXBIO INC
01/10/2023 8-K Quarterly results
12/30/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights"
06/07/2022 8-K Quarterly results
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/04/2022 8-K Quarterly results
04/07/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/07/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/25/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
03/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/01/2022 10-K Annual Report for the period ended December 31, 2021
03/01/2022 8-K Quarterly results
Docs: "REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights"
02/14/2022 SC 13G/A Redmile Group, LLC reports a 4.4% stake in REGENXBIO Inc.
02/14/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE ™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy